Table 2.
The TMA/IHC analysis of association between CD151 and clinical parameters in a local prostate patient cohort (N=181)
| Variable (N) | CD151 staining | ||
|---|---|---|---|
|
| |||
| Ave Quick Score | STD | p Value | |
| Grade | |||
| Control (21) | 287.9 | 28.3 | <0.0001 |
| BPH (7) | 262.1 | 48.7 | |
| ADT (11) | 222.7 | 85.2 | |
| Gleason 3 (69) | 242.5 | 67.7 | |
| Gleason 4 (60) | 214.6 | 83.1 | |
| Gleason 5 (13) | 242.2 | 83.7 | |
| Stage (N) | 0.1002 | ||
| T2 (80) | 246.7 | 65.6 | |
| T3 (67) | 210.3 | 85.3 | |
| T4 (6) | 246.3 | 50.4 | |
| Lymph Node Metastasis (N) | 0.9254 | ||
| Yes (7) | 229.2 | 75.3 | |
| No (146) | 230.8 | 77.5 | |
| Recurrence (N) | 0.4014 | ||
| None (111) | 229.4 | 91.9 | |
| Local (23) | 242.4 | 72.6 | |
| Distant (8) | 240.9 | 77.1 | |
| Disease-Specific Mortality (N) | 0.8633 | ||
| Survival (125) | 228.3 | 79.8 | |
| Death (9) | 231.1 | 83.9 | |